Skip to main content
. 2022 Jun 18;23(12):6803. doi: 10.3390/ijms23126803

Figure 8.

Figure 8

Immunostaining of SSI-HYB 385-06 reactivity to frameshifted calreticulin (CRTfs) and wild-type calreticulin (CRTwt). (a) Coomassie Brilliant Blue staining of recombinant CRT proteins. (b) Western blotting of SSI-HYB 385-06 reactivity to CRTfs L367 and K385 and CRTwt. (c) Western blotting of membrane from figure (b) developed with a commercial monoclonal antibody (CRT FMC 75 mAb), recognizing amino acids 34–41 (TSRWIESK) in the N-terminal of CRT. Lane 1: non-reduced CRTfs K385, Lane 2: non-reduced CRTfs L367, Lane 3: non-reduced recombinant CRT, Lane 4: reduced CRTfs K385, Lane 5: reduced CRTfs L367, Lane 6: reduced recombinant CRT.